Optimizing Therapeutic Strategies in Castration-Resistant Prostate Canceri3 Health
This activity will discuss emerging efficacy and safety data on novel therapies for nmCRPC and mCRPC, strategies to manage adverse events, and the role of imaging studies and PSA testing in evaluating treatment response.
Atorvastatin: Statins in CVD management. Is just lipid lowering enough Dr Vivek Baliga
When it comes to management of cardiovascular diseases, are achieving lipid lowering targets sufficient. Here Dr Vivek Baliga, Consultant Internal medicine discusses the additional benefits of statins in CVD in India.
Olmesartan medoxomil is an angiotensin II receptor antagonist which is used for the treatment of high blood pressure. An ester prodrug, it is completely and rapidly hydrolyzed to the active acid form. It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents
Optimizing Therapeutic Strategies in Castration-Resistant Prostate Canceri3 Health
This activity will discuss emerging efficacy and safety data on novel therapies for nmCRPC and mCRPC, strategies to manage adverse events, and the role of imaging studies and PSA testing in evaluating treatment response.
Atorvastatin: Statins in CVD management. Is just lipid lowering enough Dr Vivek Baliga
When it comes to management of cardiovascular diseases, are achieving lipid lowering targets sufficient. Here Dr Vivek Baliga, Consultant Internal medicine discusses the additional benefits of statins in CVD in India.
Olmesartan medoxomil is an angiotensin II receptor antagonist which is used for the treatment of high blood pressure. An ester prodrug, it is completely and rapidly hydrolyzed to the active acid form. It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents
Drawing on more than a decade of new work, Kim and Mauborgne show us how to move beyond competing, inspire our people's confidence, and seize new growth, guiding us step-by-step through how to take our organization from a red ocean crowded with competition to a blue ocean of uncontested market space. By combining the insights of human psychology with practical market-creating tools and real-world guidance, Kim and Mauborgne deliver the definitive guide to shift our self, our team, or our organization to new heights of confidence, market creation, and growth. They show why non-disruptive creation is as important as disruption in seizing new growth.
Blue Ocean Shift is packed with all-new research and examples of how leaders in diverse industries and organizations made the shift and created new markets by applying the process and tools outlined in the book. Whether we are a cash-strapped startup or a large, established company, non-profit or national government, we will learn how to move from red to blue oceans in a way that builds our people's confidence so that they own and drive the process.
With battle-tested lessons learned from successes and failures in the field, Blue Ocean Shift is critical reading for leaders, managers, and entrepreneurs alike. You'll learn what works, what doesn't, and how to avoid the pitfalls along the way. This book will empower us to succeed as we embark on our own blue ocean journey. Blue Ocean Shift is indispensable for anyone committed to building a compelling future.
Dapagliflozin is an AstraZeneca patented medication. In India, Sun Pharma and Abbott serve as licensed partners for dapagliflozin's distribution. While the primary patent for dapagliflozin expired in October 2020, a specific (species) patent safeguards AstraZeneca's dapagliflozin in India until May 15, 2023.
Under the brand name "Oxra®," Sun Pharma will undertake the promotion and distribution of dapagliflozin. This medication is approved for use in the United States as a monotherapy and in combination therapy to enhance glycemic control in patients with type 2 diabetes.
In China, the National Medical Products Administration (NMPA) approved dapagliflozin, both in combination with metformin and as a standalone treatment, for inadequately-controlled type-2 diabetes mellitus. It was introduced for the treatment of type 2 diabetes in China in 2018.
Japan has authorized Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D).
The Shanghai Shenkang Hospital Development Center has outlined a three-year plan to promote clinical skills and innovations in municipal hospitals, reflecting a commitment to healthcare advancements.
Efforts are being made to expand distribution channels across diverse geographical regions. AstraZeneca is closely monitoring the Indian market to secure a significant share and prevent the infringement of dapagliflozin by generic manufacturers.
Regulatory bodies are actively assessing dapagliflozin's drug and approval processes, ensuring compliance with appropriate dose and indication guidelines. For further inquiries, please contact pranayraju66@gmail.com.
Ticagrelor in acute myocardial infarctionVasif Mayan
Potential benefits of dual antiplatelet therapy beyond 1 year after an MI has not been studied
Patients with MI are at increased risk of RECURRENT ISCHAEMIC EVENTS
Intensive secondary prevention is theoretically beneficial
Finding an ideal drug with best risk-benefit ratio is a challenge
TICAGRELOR
--- Direct acting
Not a pro-drug; does not require metabolic activation
Rapid onset of inhibitory effect on the P2Y12 receptor
Greater inhibition of platelet aggregation than clopidogrel
--- Reversibly bound
Degree of inhibition reflects plasma concentration
Faster offset of effect than clopidogrel
Functional recovery of circulating platelets within ~48 hours
PLATO trial
PEGASUS TIMI trial
Drawing on more than a decade of new work, Kim and Mauborgne show us how to move beyond competing, inspire our people's confidence, and seize new growth, guiding us step-by-step through how to take our organization from a red ocean crowded with competition to a blue ocean of uncontested market space. By combining the insights of human psychology with practical market-creating tools and real-world guidance, Kim and Mauborgne deliver the definitive guide to shift our self, our team, or our organization to new heights of confidence, market creation, and growth. They show why non-disruptive creation is as important as disruption in seizing new growth.
Blue Ocean Shift is packed with all-new research and examples of how leaders in diverse industries and organizations made the shift and created new markets by applying the process and tools outlined in the book. Whether we are a cash-strapped startup or a large, established company, non-profit or national government, we will learn how to move from red to blue oceans in a way that builds our people's confidence so that they own and drive the process.
With battle-tested lessons learned from successes and failures in the field, Blue Ocean Shift is critical reading for leaders, managers, and entrepreneurs alike. You'll learn what works, what doesn't, and how to avoid the pitfalls along the way. This book will empower us to succeed as we embark on our own blue ocean journey. Blue Ocean Shift is indispensable for anyone committed to building a compelling future.
Dapagliflozin is an AstraZeneca patented medication. In India, Sun Pharma and Abbott serve as licensed partners for dapagliflozin's distribution. While the primary patent for dapagliflozin expired in October 2020, a specific (species) patent safeguards AstraZeneca's dapagliflozin in India until May 15, 2023.
Under the brand name "Oxra®," Sun Pharma will undertake the promotion and distribution of dapagliflozin. This medication is approved for use in the United States as a monotherapy and in combination therapy to enhance glycemic control in patients with type 2 diabetes.
In China, the National Medical Products Administration (NMPA) approved dapagliflozin, both in combination with metformin and as a standalone treatment, for inadequately-controlled type-2 diabetes mellitus. It was introduced for the treatment of type 2 diabetes in China in 2018.
Japan has authorized Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D).
The Shanghai Shenkang Hospital Development Center has outlined a three-year plan to promote clinical skills and innovations in municipal hospitals, reflecting a commitment to healthcare advancements.
Efforts are being made to expand distribution channels across diverse geographical regions. AstraZeneca is closely monitoring the Indian market to secure a significant share and prevent the infringement of dapagliflozin by generic manufacturers.
Regulatory bodies are actively assessing dapagliflozin's drug and approval processes, ensuring compliance with appropriate dose and indication guidelines. For further inquiries, please contact pranayraju66@gmail.com.
Ticagrelor in acute myocardial infarctionVasif Mayan
Potential benefits of dual antiplatelet therapy beyond 1 year after an MI has not been studied
Patients with MI are at increased risk of RECURRENT ISCHAEMIC EVENTS
Intensive secondary prevention is theoretically beneficial
Finding an ideal drug with best risk-benefit ratio is a challenge
TICAGRELOR
--- Direct acting
Not a pro-drug; does not require metabolic activation
Rapid onset of inhibitory effect on the P2Y12 receptor
Greater inhibition of platelet aggregation than clopidogrel
--- Reversibly bound
Degree of inhibition reflects plasma concentration
Faster offset of effect than clopidogrel
Functional recovery of circulating platelets within ~48 hours
PLATO trial
PEGASUS TIMI trial
Y Combinator 創業者 Paul Graham からのスタートアップへのアドバイス(スタートアップが迷った時に読む Paul Graham から...Takaaki Umada
スタートアップが迷った時に読む Paul Graham からのアドバイス集です。これまでのエッセイをトピック別にまとめ、アドバイスを抽出しました。
Y Combinator のプログラムを通して、数百社のスタートアップに対して アドバイスを続け、Y Combinator が他アクセラレーターとは別格のスタートアップを続々と輩出してこれたのは、おそらく Paul Graham のスタートアップへのアドバイスが的確だったからだろう、と思っています。なので日本でも Paul Graham のエッセイにアクセスしやすくなれば、スタートアップの皆さんの架空の相談先の一つとして役立つのではないか、と思いまとめた次第です。
併読して役立つであろうスタンフォード大学の How to Start a Startup のサマリーは以下においています。
http://www.slideshare.net/takaumada/how-to-start-a-startup-42996994